Navigation Links
The effect of treatment with antibiotics and vaccination against Q fever in sheep
Date:5/30/2012

e few antibiotics authorized for sheep that are effective against intracellular bacteria like Coxiella burnetii.

Vaccination, a promising method of control

The use of an inactivated vaccine to control the disease offered more promising results. The vaccine Coxevac was used and its effectiveness was proven in the short (1 year) and long term (4 years). No immediate effects were noticed during the first year following vaccination, because the flocks studied had a high percentage of infected animals. However, with routine annual vaccinations it was possible to gradually reduce the infection until its disappearance after four years of vaccination.

The vaccine was beneficial in controlling abortions which, after the first year of vaccination, were significantly reduced (<2%). Q fever is responsible for abortion rates between approximately 6% and 10% of the ewes in an infected flock.

After four years of vaccination, the absence of the infection in the animals did not necessarily mean that the bacteria Coxiella burnetii had been eradicated on the sheep flock, since this bacterium is very persistant in the environment, and it remains present in sheep premises (surfaces, floor, aerosols) for long periods of time. So Neiker-Tecnalia recommends that after an outbreak of Q fever in a sheep flock, vaccination should be implemented for a period of five years at least. It is very important that replacement lambs are immunised against the bacterium when they reach three months of age.

Means of eliminating Coxiella burnetti

Neiker-Tecnalia scientists found that the main Coxiella burnetti shedding routes in sheep are vaginal fluids and faeces; and to a lesser extent, milk. Bacterial shedding through milk is basically concentrated in the first month after lambing, while vaginal and faecal excretion is more prolonged in time. Bacterial excretion favours the generation of contaminated aerosols and
'/>"/>

Contact: Irati Kortabitarte
i.kortabitarte@elhuyar.com
34-943-363-040
Elhuyar Fundazioa
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Novel discovery by NUS scientists paves the way for more effective treatment of cancers
2. Lab tests show arthritis drug effective against global parasite
3. New evidence that many genes of small effect influence economic decisions and political attitudes
4. The gut could reveal effect of climate change on fish
5. WSU researchers say genes and vascular risk modify effects of aging on brain and cognition
6. Psychiatric medication effects on brain structure
7. Climatic effects of a solar minimum
8. First-of-its-kind study reveals surprising ecological effects of earthquake and tsunami
9. University of Nevada, Reno first to show transgenerational effect of antibiotics
10. Kinesiology team gets $975,000 Defense grant to study effects of heavy loads on soldiers
11. As deadly cat disease spreads nationally, MU veterinarian finds effective treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... April 27, 2015  For more than four decades, ... has been the premier worldwide event for the unmanned ... a must-attend event for any local, national, or trade ... emerging commercial markets and current applications of unmanned technologies. ... this projected $48 billion industry, and how it will ...
(Date:4/27/2015)... , Apr. 27, 2015 Profile Solutions, ... control and security systems is pleased to announce that ... as a consultant and member of its scientific advisory ... widely known as a thought leader in technology-enhanced learning ... Technology Group, and has published studies and books focused ...
(Date:4/20/2015)... , April 20, 2015 Huntington Memorial ... Valley to implant a new miniaturized, wireless monitoring sensor ... is the first and only FDA-approved heart failure monitoring ... admissions when used by physicians to manage heart failure. ... that is implanted in the pulmonary artery (PA) during ...
Breaking Biology News(10 mins):UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 3UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 4UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 5Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3
... cystic fibrosis (CF) patients with targeted treatment in ... French clinical trial published today in BMC Medicine ... with a rare genetic stop mutation responded positively ... Sermet-Gaudelus of Faculté de Médicine Necker in Paris ...
... with puzzles or chess, the reason may be in your ... geneticists at Washington University School of Medicine in St. Louis, ... gene that activates signaling pathways in the brain influences one ... gene, CHRM2, and performance IQ, which involves a person's ability ...
... that employs RNA, a tiny chemical cousin of DNA, to ... which nudging a gene awake would help alleviate disease, researchers ... method, which is being developed by UT Southwestern scientists, also ... the role that genes play in human health. ...
Cached Biology News:Genes and genius: Researchers confirm association between gene and intelligence 2Genes and genius: Researchers confirm association between gene and intelligence 3Novel laboratory technique nudges genes into activity 2Novel laboratory technique nudges genes into activity 3
(Date:5/21/2015)... TORONTO , May 21, 2015 /PRNewswire/ - SQI ... SQIDF),a life sciences company that develops and commercializes proprietary ... its financial and operational results for the second fiscal ... the quarter the Company continued to advance business with ... Andrew Morris , President and CEO of SQI. ...
(Date:5/21/2015)... CA (PRWEB) May 21, 2015 ... has announced a partnership with PicnicHealth, a healthcare ... patients. Participants diagnosed with Inflammatory Bowel Disease (IBD) ... as a complementary uBiome research kit. Both companies ... , For more information on ...
(Date:5/21/2015)... May 21, 2015  CytRx Corporation (NASDAQ: ... specializing in oncology, today announced positive updated results ... aldoxorubicin for the treatment of unresectable glioblastoma multiforme ... open-label, multisite trial is designed to investigate the ... whose tumors have progressed following prior treatment with ...
(Date:5/21/2015)... 2015 Tunnell Consulting, Inc. ... as senior statistician and Principal, a position to which ... the management and analysis of complex and large data ... , “We’re delighted to have Julia join the Tunnell ... said Dr. Philippe Cini, Group Vice President and leader ...
Breaking Biology Technology:SQI Diagnostics Reports Second Quarter Financial Results 2SQI Diagnostics Reports Second Quarter Financial Results 3SQI Diagnostics Reports Second Quarter Financial Results 4SQI Diagnostics Reports Second Quarter Financial Results 5SQI Diagnostics Reports Second Quarter Financial Results 6SQI Diagnostics Reports Second Quarter Financial Results 7SQI Diagnostics Reports Second Quarter Financial Results 8uBiome Partners with PicnicHealth 2uBiome Partners with PicnicHealth 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Julia O’Neill Joins Tunnell Consulting’s Operational and Process Improvement Practice 2
... , , MINNEAPOLIS, Aug. 4 Techne ... has decided to pay a dividend of $0.25 per share for the ... August 31, 2009 to all common shareholders of record on August 17, ... Directors on a quarterly basis. , , Techne Corporation ...
... CRANBURY, N.J., Aug. 4 Palatin Technologies, Inc. (NYSE Amex: ... a Notice of Allowance from the U.S. Patent and Trademark ... Natriuretic Peptide Constructs." Allowed claims cover a family of ... including PL-3994, Palatin,s lead heart failure drug candidate. Palatin expects ...
... BEIJING, Aug. 4 /PRNewswire-Asia/ -- Sinovac Biotech Ltd.,(NYSE AMEX: ... China, announced today,that the clinical trial of its A/H1N1 influenza ... shot of the vaccine and, during the,three day observation period, ... and reliable in humans. , The ...
Cached Biology Technology:Palatin Technologies, Inc. Receives U.S. Patent Allowance for Heart Failure Drug Candidate 2Palatin Technologies, Inc. Receives U.S. Patent Allowance for Heart Failure Drug Candidate 3Revised: Sinovac Provides Update on Clinical Trial for H1N1 Vaccine Trials 2Revised: Sinovac Provides Update on Clinical Trial for H1N1 Vaccine Trials 3
...
Highly efficient electroporation solution suitable for transfection of plasmid DNA, oligonucleotides and siRNA. Compatible with all common electroporators....
Removes polysaccharide and phenolic inhibitors of PCR; yields DNA greater than 50 kb in length...
...
Biology Products: